ROP ocular outcomes after Bevacizumab treatment
Reviewed by Fiona Rowe

The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of prematurity (ROP)); 2) infants treated with laser photocoagulation for ROP (three with zone 1 and 25 with zone 2); and 3) infants with spontaneous regressed ROP without any anatomical sequelae (n=21). Incidence of myopia was significantly lower in group 3 (11.8%) than groups 1 (40.7%) and 2 (32.7%). Group 2 had significantly thicker lenses than groups 1 and 3. Group 1 had significant association between spherical equivalent and axial length; reducing spherical equivalent with increasing axial length. Group 2 had significant association between spherical equivalent and anterior chamber depth; both positively correlated.

Evaluation of refractive errors and ocular biometric outcomes after intravitreal Bevacizumab for retinopathy of prematurity.
Gunay M, Sekeroglu MA, Bardak H, et al.
STRABISMUS
2016;24(2):84-8.